Symptoms and Findings Associated with Pulmonary Vascular Disease

Vasoreactive phenotype in children with pulmonary arterial hypertension and syncope

Alexandra N. Linder, Jill Hsia, Sheila V. Krishnan, Erika B. Rosenzweig, Usha S. KrishnanColumbia University Irving Medical Center and New York Presbyterian Hospital. Children’s Hospital of Philadelphia, Philadelphia. Stonybrook University School of Medicine.United States European Respiratory Journal Open ResearchERJ Open Res 2022; 8: DOI: 10.1183/23120541.00223-2022 AbstractBackground: Syncope in Group 1 pulmonary arterial hypertension (PAH) is an independent […]

Vasoreactive phenotype in children with pulmonary arterial hypertension and syncope Read More »

Abnormal platelet aggregation in pediatric pulmonary hypertension

Stephanie S. Handler, Jing Jin, Michelle T. Ogawa, Jeffrey A. Feinstein, Clara LoMedical College of Wisconsin. Stanford University.United States Pulmonary CirculationPulm Circ 2022; 12: DOI: 10.1002/pul2.12104 AbstractEndogenous prostacyclin stimulates pulmonary vasodilation and inhibits platelet aggregation. For the synthetic analog treprostinil, used in the treatment of pulmonary hypertension (PH), conflicting, anecdotal evidence exists regarding its effects on

Abnormal platelet aggregation in pediatric pulmonary hypertension Read More »

Risk stratification in adult and pediatric pulmonary arterial hypertension: A systematic review

Chantal Lokhorst, Sjoukje van der Werf, Rolf M. F. Berger, Johannes M. DouwesUniversity of Groningen, Beatrix Children’s Hospital and University Medical Center GroningenNetherlands Frontiers in Cardiovascular MedicineFront Cardiovasc Med 2022; 9: 1035453DOI: 10.3389/fcvm.2022.1035453 AbstractIntroduction: Currently, risk stratification is the cornerstone of determining treatment strategy for patients with pulmonary arterial hypertension (PAH). Since the 2015 European Society of

Risk stratification in adult and pediatric pulmonary arterial hypertension: A systematic review Read More »

Scroll to Top